NV
Novozymes A/S
NVZMF · OTC
$63.30 -2.27% (-$1.47)
1M -11.00%
Market Cap 26.0B €
P/E Ratio 41.25x
Div. Yield 1.62%
ROE 5.78%
Bulios Fair Price
$35.76
43.5% downside
Current Price
$63.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NVZMF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
18 /100
Expensive EV/EBITDA 20.03x
P/S 6.06x
P/B 2.34x
Growth
1 /100
Declining Rev. growth 38.13%
FCF growth 12.38%
Book val. growth 7.77%
Profitability
100 /100
Strong Net margin 14.70%
Op. margin 20.98%
FCF margin 12.74%
Quality
44 /100
Average ROE 5.78%
ROA 3.81%
Asset turnover 0.26x
Debt
90 /100
Low Current ratio 1.74x
Int. coverage 22.09x
Net debt/EBITDA 1.91x
Stability
43 /100
Moderate Rev. volatility 48.54%
EPS volatility 90.56%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NVZMF
Online
Sector
Basic Materials
Industry
Chemicals - Specialty
CEO
Ester Baiget
Employees
11,641
Headquarters
Lyngby
Upcoming events
05 NOV
Earnings
Upcoming earnings report